Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study.
STRIVE study
episodic migraines
erenumab
monthly migraine attacks
monthly migraine days
Journal
Cephalalgia : an international journal of headache
ISSN: 1468-2982
Titre abrégé: Cephalalgia
Pays: England
ID NLM: 8200710
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
pubmed:
4
5
2021
medline:
18
1
2022
entrez:
3
5
2021
Statut:
ppublish
Résumé
This post-hoc analysis was conducted to evaluate the effect of erenumab on monthly migraine days, monthly migraine attacks, and attack duration in patients with episodic migraine to investigate whether erenumab actually prevents the occurrence of migraine attacks and/or shortens them. We conducted a post-hoc analysis of the data from the STRIVE study, in 955 patients with episodic migraine. Relative changes from baseline to mean over months 4, 5 and 6 of the double-blind treatment phase in monthly migraine days, monthly migraine attacks and mean migraine attack duration were assessed. Erenumab reduced monthly migraine days and monthly migraine attacks compared with placebo in a similar way. Erenumab had only a minor impact on shortening the duration of migraine attacks. These post-hoc analyses demonstrate that the decrease in monthly migraine days by erenumab is mainly driven by a reduction in the frequency of monthly migraine attacks and to a much lesser extent by shortening the duration of migraine attacks.Trial registration: This study is registered at ClinicalTrials.gov (NCT02456740).
Sections du résumé
BACKGROUND
This post-hoc analysis was conducted to evaluate the effect of erenumab on monthly migraine days, monthly migraine attacks, and attack duration in patients with episodic migraine to investigate whether erenumab actually prevents the occurrence of migraine attacks and/or shortens them.
METHODS
We conducted a post-hoc analysis of the data from the STRIVE study, in 955 patients with episodic migraine. Relative changes from baseline to mean over months 4, 5 and 6 of the double-blind treatment phase in monthly migraine days, monthly migraine attacks and mean migraine attack duration were assessed.
RESULTS
Erenumab reduced monthly migraine days and monthly migraine attacks compared with placebo in a similar way. Erenumab had only a minor impact on shortening the duration of migraine attacks.
CONCLUSION
These post-hoc analyses demonstrate that the decrease in monthly migraine days by erenumab is mainly driven by a reduction in the frequency of monthly migraine attacks and to a much lesser extent by shortening the duration of migraine attacks.Trial registration: This study is registered at ClinicalTrials.gov (NCT02456740).
Identifiants
pubmed: 33939497
doi: 10.1177/03331024211010308
pmc: PMC8504413
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Calcitonin Gene-Related Peptide Receptor Antagonists
0
erenumab
I5I8VB78VT
Banques de données
ClinicalTrials.gov
['NCT02456740']
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1262-1267Références
Lancet Neurol. 2014 Sep;13(9):885-92
pubmed: 25127173
J Pharmacol Exp Ther. 2016 Jan;356(1):223-31
pubmed: 26559125
Lancet Neurol. 2016 Apr;15(4):382-90
pubmed: 26879279
Lancet Neurol. 2017 Jun;16(6):425-434
pubmed: 28460892
Cephalalgia. 2020 Sep;40(10):1026-1044
pubmed: 32722936
N Engl J Med. 2017 Nov 30;377(22):2123-2132
pubmed: 29171821
Lancet. 2018 Nov 24;392(10161):2280-2287
pubmed: 30360965
Lancet Neurol. 2020 Sep;19(9):727-737
pubmed: 32822633
Cephalalgia. 2018 May;38(6):1026-1037
pubmed: 29471679